Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials

Radiology

Volumn 224, Issue 1, 2002, Pages 47-54

  Cammà, Calogero ^a   Schepis, Filippo ^a   Orlando, Ambrogio ^a   Albanese, Maddalena ^a   Shahied, Lillian ^a   Trevisani, Franco ^a   Andreone, Pietro ^a   Craxì, Antonio ^a   Cottone, Mario ^a  

^a CNR   (Italy)

Author keywords

Efficacy study; Liver neoplasms; Liver neoplasms, chemotherapeutic embolization; Radiology and radiologists, outcomes studies

Indexed keywords

ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DATA BASE; EVIDENCE BASED MEDICINE; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL;

EID: 0036085956     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2241011262     Document Type: Article

References (54)

1. Rising incidence of hepatocellular carcinoma in the United States
2. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience
3. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
4. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - An impossible meta-analysis?
5. The combination therapy of transcatheter arterial embolization and percutaneous ethanol injection for small hepatocellular carcinoma: Randomized controlled study
6. Treatment on unresectable hepatocellular carcinoma: Results of a randomized controlled trial
7. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: A randomized controlled trial
8. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma
9. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma
10. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: Intra-arterial iodine-131-iodized oil versus medical support
11. Lipiodolization with or without gelatin sponge in hepatic chemoembolization for hepatocellular carcinoma
12. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma
13. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial
14. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution
15. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil
16. Studies on the chemotherapy with 5-fluorouracil in transcatheter chemoembolization (TAE) treated patients with resectable on non-resectable hepatocellular carcinoma
17. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: A comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study)
18. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: A comparison of L-TAE with farmorubicin and L-TAE with adriamycin (second cooperative study)
19. Comparison of the anticancer effect ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection
20. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma
21. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: A comparison between L-TAE with farmorubicin and L-TAE with adriamycin-preliminary results (second cooperative study)
22. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma
23. Transcatheter arterial embolization with or without Cisplatin treatment of hepatocellular carcinoma
24. A prospective randomized evaluation of a compound of Tegafur and Uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization
25. Unresectable hepatocellular carcinoma: Analysis of prognostic factors in transcatheter management
26. Epirubicinlipiodol chemotherapy versus 13 liodinelipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma
27. Treatment of large HCC: Transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization
28. Prospective and randomized trial of lipiodoltranscatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A comparison of epirubicin and doxorubicin (second cooperative study)
29. Prospective randomized trial of chemoembolization versus intraarterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma
30. A prospective randomized administration of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization
31. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma
32. Post-operative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma
33. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal
34. Hepatocellular carcinoma: Surgical resection versus surgical resection combined with pre and post operative locoregional immunotherapy-chemotherapy - A prospective randomized study
35. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients: Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone
36. Interleukin-6 in transcatheter embolization for patients with hepatocellular carcinoma
37. Intra-arterial and intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma: A randomized comparison
38. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion
39. Unresectable hepatocellular carcinoma: Lack of efficacy of lipiodol chemoembolization-final results of a multicenter randomized trial
40. Essai randomisé de la chimioembolisation lipiodolée dans le traitement du carcinome hépatocellulaire (CHC) non résectable
41. Randomised controlled trial of chemo-embolization vs intra-arterial injection of 131 I-labelled iodized oil (Lipiocis) in the treatment of hepatocellular carcinoma
42. Treatment of hepatocellular carcinoma by transarterial embolization (TAE): A prospective placebo controlled trial
43. Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma
44. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference
45. Quantitative synthesis in systematic reviews
46. Quality evolution and clinical implications of randomized, controlled trials on the treatment of lung cancer: A lost opportunity for meta-analysis
47. The hazards of scoring the quality of clinical trials for meta-analysis
48. Meta-analysis in clinical trials
49. Statistical aspects of the analysis of data from retrospective studies of disease
50. Tutorial in biostatistics metaanalysis: Formulating, evaluating, combining, and reporting
51. Explaining heterogeneity in meta-analysis: A comparison of methods
52. Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation
53. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization
54. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: Comparison of planned periodic chemoembolization and chemoembolization based on tumor response